APA (7th ed.) Citation

J, R., M, S., L, P., A, N., T, G., B, T., . . . MBA, v. D. (2023). Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial. International journal of molecular sciences, 24(18), . https://doi.org/10.3390/ijms241814315

Chicago Style (17th ed.) Citation

J, Rousel, et al. "Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis Versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial." International Journal of Molecular Sciences 24, no. 18 (2023). https://doi.org/10.3390/ijms241814315.

MLA (9th ed.) Citation

J, Rousel, et al. "Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis Versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial." International Journal of Molecular Sciences, vol. 24, no. 18, 2023, https://doi.org/10.3390/ijms241814315.